دورية أكاديمية
أعرض في EDS

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia.

التفاصيل البيبلوغرافية
العنوان: A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia.
المؤلفون: Osmanova DZ; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014.; National Research Tomsk State University, Lenin Avenue, Tomsk, Russian Federation, 36., Freidin MB; Department of Twin Research and Genetic Epidemiology, School of Live Course Sciences, King's College London, Lambeth Palace Road, London, SE1 7EH, UK.; Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, Naberezhnaya Ushaiki str, Tomsk, Russian Federation, 10., Fedorenko OY; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014.; National Research Tomsk Polytechnic University, Lenin Avenue, Tomsk, Russian Federation, 30., Pozhidaev IV; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014.; National Research Tomsk State University, Lenin Avenue, Tomsk, Russian Federation, 36., Boiko AS; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014., Vyalova NM; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014., Tiguntsev VV; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014., Kornetova EG; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014., Loonen AJM; Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713, AV, Groningen, The Netherlands.; GGZ Westelijk Noord-Brabant, Hoofdlaan 8, 4661 AA, Halsteren, The Netherlands., Semke AV; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014., Wilffert B; Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713, AV, Groningen, The Netherlands.; University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, University of Groningen, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands., Bokhan NA; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014.; National Research Tomsk State University, Lenin Avenue, Tomsk, Russian Federation, 36., Ivanova SA; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, Russian Federation, 634014. ivanovaniipz@gmail.com.; National Research Tomsk Polytechnic University, Lenin Avenue, Tomsk, Russian Federation, 30. ivanovaniipz@gmail.com.
المصدر: BMC medical genetics [BMC Med Genet] 2019 Apr 09; Vol. 20 (Suppl 1), pp. 47. Date of Electronic Publication: 2019 Apr 09.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968552 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2350 (Electronic) Linking ISSN: 14712350 NLM ISO Abbreviation: BMC Med Genet Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2000-
مواضيع طبية MeSH: Pharmacogenomic Testing*, Antipsychotic Agents/*adverse effects , Dopamine/*metabolism , Dopamine Plasma Membrane Transport Proteins/*genetics , Hyperprolactinemia/*chemically induced , Receptors, Dopamine/*genetics , Schizophrenia/*drug therapy, Adult ; Female ; Humans ; Hyperprolactinemia/genetics ; Male ; Middle Aged ; Polymorphism, Single Nucleotide ; Schizophrenia/genetics ; Siberia
مستخلص: Background: Hyperprolactinemia (HPRL) is a classical side effect of antipsychotic drugs primarily attributed to blockade of dopamine D2 receptors (DRD2s) on the membranes of lactotroph cells within the pituitary gland. Certain antipsychotic drugs, e.g. risperidone, are more likely to induce HPRL because of relative accumulation within the adenohypophysis. Nevertheless, due to competition for pituitary DRD2s by high dopamine levels may limit antipsychotic-induced HPRL. Moreover, the activity of prolactin-producing lactotrophs also depends on other hormones which are regulated by the extra-pituitary activity of dopamine receptors, dopamine transporters, enzymes of neurotransmitter metabolism and other factors. Polymorphic variants in the genes coding for these receptors and proteins can have functional significance and influence on the development of hyperprolactinemia.
Methods: A set of 41 SNPs of genes for dopamine receptors DRD1, DRD2, DRD3, DRD4, the dopamine transporter SLC6A3 and dopamine catabolizing enzymes MAOA and MAOB was investigated in a population of 446 Caucasians (221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20) with and without HPRL who were treated with classical and/or atypical antipsychotic drugs. Additive genetic model was tested and the analysis was carried out in the total group and in subgroup stratified by the use of risperidone/paliperidone.
Results: One statistically significant association between polymorphic variant rs1799836 of MAOB gene and HPRL in men was found in the total group. Furthermore, the rs40184 and rs3863145 variants in SLC6A3 gene appeared to be associated with HPRL in the subgroup of patients using the risperidone/paliperidone, but not with HPRL induced by other antipsychotic drugs.
Conclusions: Our results indicate that genetic variants of MAOB and SLC6A3 may have consequences on the modulation of prolactin secretion. A further search for genetic markers associated with the development of antipsychotic-related hyperprolactinemia in schizophrenic patients is needed.
References: Brain Res. 2011 Oct 28;1420:106-13. (PMID: 21955727)
Eur Neuropsychopharmacol. 2008 Mar;18(3):157-69. (PMID: 17683917)
Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):873-9. (PMID: 18351593)
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1026-32. (PMID: 20580759)
Biol Psychiatry. 2010 Feb 1;67(3):255-62. (PMID: 19897178)
Genet Mol Res. 2016 Jul 14;15(2):. (PMID: 27421021)
Ann Hum Genet. 2006 May;70(Pt 3):293-303. (PMID: 16674552)
Schizophr Res. 2012 Dec;142(1-3):206-8. (PMID: 23036699)
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20552-7. (PMID: 18077373)
Pharmacol Ther. 2014 Aug;143(2):133-52. (PMID: 24607445)
Hum Psychopharmacol. 2010 Jul;25(5):397-403. (PMID: 20589923)
Pharmacol Rep. 2009 Nov-Dec;61(6):1024-33. (PMID: 20081237)
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7625-8. (PMID: 2529545)
J Biol Chem. 1978 Apr 10;253(7):2244-53. (PMID: 416027)
Am J Psychiatry. 1999 Jun;156(6):876-84. (PMID: 10360126)
Biol Psychiatry. 2006 Sep 15;60(6):570-7. (PMID: 16893532)
J Endocrinol. 2015 Aug;226(2):T101-22. (PMID: 26101377)
PLoS One. 2014 Jul 15;9(7):e102556. (PMID: 25025909)
J Clin Psychopharmacol. 2013 Oct;33(5):593-9. (PMID: 23963056)
CNS Neurol Disord Drug Targets. 2006 Feb;5(1):45-56. (PMID: 16613553)
J Hum Reprod Sci. 2013 Jul;6(3):168-75. (PMID: 24347930)
Endocr Regul. 1998 Jun;32(2):71-75. (PMID: 10330520)
J Neurosci. 1992 May;12(5):1977-99. (PMID: 1578281)
Pharmacogenomics. 2011 Aug;12(8):1193-211. (PMID: 21843066)
Endocr Rev. 1985 Fall;6(4):564-89. (PMID: 2866952)
Psychiatry Res. 2000 Jul 24;95(1):9-23. (PMID: 10904119)
Ann Neurol. 1993 Apr;33(4):368-72. (PMID: 8489207)
J Psychiatr Res. 2008 Sep;42(11):884-93. (PMID: 18086475)
Schizophr Res. 2004 Mar 1;67(1):75-85. (PMID: 14741327)
World J Biol Psychiatry. 2017 Apr;18(3):239-246. (PMID: 27654063)
Neuropsychobiology. 2008;58(2):65-70. (PMID: 18832861)
Endocrinology. 2000 Jan;141(1):366-74. (PMID: 10614659)
Psychiatr Danub. 2016 Jun;28(2):127-31. (PMID: 27287786)
J Neural Transm (Vienna). 2009 Oct;116(10):1323-34. (PMID: 19657584)
CNS Drugs. 2014 May;28(5):421-53. (PMID: 24677189)
Neuropsychiatr Dis Treat. 2017 Dec 05;13:2935-2943. (PMID: 29255361)
Aust N Z J Obstet Gynaecol. 2011 Aug;51(4):321-4. (PMID: 21806583)
Bioinformatics. 2007 Mar 1;23(5):644-5. (PMID: 17267436)
Acta Endocrinol (Copenh). 1991 Dec;125(6):621-7. (PMID: 1789057)
Hum Psychopharmacol. 2005 Oct;20(7):493-500. (PMID: 16118767)
Neuroscience. 1996 Feb;70(3):755-74. (PMID: 9045087)
J Clin Endocrinol Metab. 1998 Mar;83(3):761-4. (PMID: 9506722)
Ann Clin Biochem. 2010 Jul;47(Pt 4):292-300. (PMID: 20592331)
Psychiatry Res. 2014 Oct 30;219(2):261-7. (PMID: 24930580)
J Psychopharmacol. 2013 Apr;27(4):343-8. (PMID: 23118020)
Schizophr Res. 2017 Apr;182:110-114. (PMID: 27776952)
Psychosomatics. 2014 Jan-Feb;55(1):29-36. (PMID: 24140188)
Psychiatry Clin Neurosci. 2006 Dec;60(6):764-7. (PMID: 17109713)
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):475-81. (PMID: 19439249)
Psychiatry Res. 2015 Sep 30;229(1-2):586-8. (PMID: 26213377)
Endocrinology. 1980 Feb;106(2):526-9. (PMID: 7353525)
Psychopharmacology (Berl). 2004 Apr;173(1-2):27-31. (PMID: 14712338)
Neuroendocrinology. 1981 Feb;32(2):108-13. (PMID: 6782499)
BMC Psychiatry. 2013 Aug 22;13:214. (PMID: 23968123)
AAPS J. 2005 Dec 20;7(4):E847-51. (PMID: 16594636)
Pharmacogenetics. 1997 Dec;7(6):479-84. (PMID: 9429233)
Behav Brain Funct. 2011 Oct 06;7:42. (PMID: 21978760)
Eur Neuropsychopharmacol. 2001 Dec;11(6):449-55. (PMID: 11704422)
Drugs. 2004;64(20):2291-314. (PMID: 15456328)
Lancet. 2009 Aug 22;374(9690):635-45. (PMID: 19700006)
Am J Med Genet B Neuropsychiatr Genet. 2011 Jul;156B(5):613-9. (PMID: 21595009)
Hum Mol Genet. 2008 Mar 1;17(5):747-58. (PMID: 18045777)
فهرسة مساهمة: Keywords: Antipsychotics; Dopamine receptors genes; Dopamine transporter SLC6A3; Hyperprolactinemia; Monoamine oxidase (MAO)
المشرفين على المادة: 0 (Antipsychotic Agents)
0 (Dopamine Plasma Membrane Transport Proteins)
0 (Receptors, Dopamine)
0 (SLC6A3 protein, human)
VTD58H1Z2X (Dopamine)
تواريخ الأحداث: Date Created: 20190411 Date Completed: 20200402 Latest Revision: 20231006
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6454588
DOI: 10.1186/s12881-019-0773-3
PMID: 30967134
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2350
DOI:10.1186/s12881-019-0773-3